Abstract:Background: Inflammation and angiogenesis play prominent roles in inflammatory bowel disease.Thalidomide, as an inhibitor of inflammation and angiogenesis, is a new potent therapy option for refractory Crohn's disease (CD).Objective: To evaluate the long-term clinical efficacy and safety of thalidomide therapy in pediatric CD patients who failed conventional medications or had tuberculosis; and investigate the effect of oral thalidomide therapy on angiogenesis in pediatric CD patients.Methods: A total of 17 patients (9 boys and 8 girls) aged 11.8 ± 5.2 years with refractory CD diagnosed at the mean age of 10.2 ± 4.3 years were included in this study.Patients were administered thalidomide (2 mg/kg/d) orally at baseline.The clinical activity of disease was assessed with the Pediatric Crohn's Disease Activity Index (PCDAI) at baseline and at 1, 3, 6, 12 months.Weight-for-age Z score, laboratory evaluations and reduction in corticosteroid requirement were also used to assess clinical response.Adverse effects were recorded at each visit.In addition, colonoscopy examination after treatment was performed in 10 patients during this study.Vascular endothelial growth factor (VEGF) and CD31 for microvessel density were measured by immunohistochemistry in the pre-treatment, post-treatment and control groups.Intestinal mucosal VEGF protein levels were also evaluated with western blot.Results: All 15 patients completed 12 months follow-up.Mean PCDAI was 41.0±11.9 at baseline, the values at 1, 3, 6 and 12 months decreased to 15.2±9.6,5.3±5.0,3±3.4 and 2.3±2.6,respectively.Eleven of 12 patients who required corticosteroids for management were off the drug at 12 months.The mean period was 3.1±1.5 months.ESR, CRP and PLT levels decreased after thalidomide treatment, and there was an increase in hemoglobin level.Furthermore, a significant increase in weight-for-age Z score was observed 12 months after administration of thalidomide.Three patients experienced fatigue, and 2 drowsiness during therapy.One patient presented with transient liver function abnormity.Immunohistochemical expression of VEGF and CD31 in refractory CD patients was higher than those in the control group, and the levels were significantly reduced after thalidomide therapy.The VEGF levels in intestinal mucosa were down-regulated in post-treatment group compared with pre-treatment group.Conclusion: Thalidomide long-term treatment appears to be clinically effective and well tolerated.It is a relatively safe drug in refractory Crohn's disease patients and those with tuberculosis.Mechanism of action of thalidomide therapy in CD might be associated with inhibition of angiogenesis which may be mediated by suppression of VEGF expression in the mucosa.Colonoscopy showed obvious mucosal healing in pediatric CD patients.Mucosal appearances before (A, B, C) and after (D, E, F) administration of thalidomide. S-452 AGA AbstractsMean values of the laboratory parameters-ESR(A), CRP(B), PLT (C), Hb (D)-at baseline and 1, 3, 6, 12 months(m).Results showed a significant improvement in blood tests.ESR=erythrocyte sedimentation rate; CRP=C-reactive protein; Hb=hemoglobin; PLT=platelet count.

Safety and efficacy of thalidomide in treatment of gastrointestinal bleeding secondary to angioectasias: a systematic review and meta-analysis

Efficacy and safety of thalidomide in gastrointestinal angiodysplasias: systematic review and meta-analysis with trial sequential analysis of randomized controlled trials

Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia.

The Efficacy and Safety of Thalidomide in the Treatment of Refractory Crohn's Disease in Adults: a Double-Center, Double-Blind, Randomized–controlled Trial

Novel Use of Low-dose Thalidomide in Refractory Gastrointestinal Bleeding in Left Ventricular Assist Device Patients

Thalidomide for Recurrent Small Intestinal Gastrointestinal Bleeding

Clinical Efficacy and Mechanism of Action of Thalidomide in Pediatric Patients With Refractory Crohn's Disease

Efficacy, Safety, and Potential Biomarkers of Thalidomide Plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma

Thalidomide As a Treatment for Inflammatory Bowel Disease in Children and Adolescents: A Systematic Review

Thalidomide as a treatment for inflammatory bowel disease in children and adolescents: A systematic review.

Observation on the Effect of Thalidomide for the Treatment of Crohn's Disease

Thalidomide Improves Prevention of Chemotherapy-Induced Gastrointestinal Side Effects Following a Modified FOLFOX7 Regimen: Results of a Prospective Randomized Crossover Study

Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial

Efficacy and Safety of Thalidomide As a Pre-Medication of Chemotherapy-Induced Nausea and Vomiting (CINV) Following Highly Emetogenic Chemotherapy (HEC): A Systematic Review and Meta-Analysis

Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials

Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial

Thalidomide for management of refractory oral mucosal diseases

Efficacy and Safety of Thalidomide for Chemotherapy-induced Nausea and Vomiting

Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non–Small-Cell Lung Cancer

Efficacy and safety of thalidomide in children with monogenic autoinflammatory diseases: a single-center, real-world-evidence study

Long‐term Outcomes of Thalidomide in Pediatric Crohn's Disease